Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease

Souvarish Sarkar1, Hai M Nguyen2, Emir Malovic1

  • 1Parkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.

Insights

Microglial Kv1.3 channels are upregulated in Parkinson's disease (PD). Targeting these channels with PAP-1 inhibits neuroinflammation and neurodegeneration, offering a potential therapeutic strategy for PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglial activation is a hallmark of neurodegenerative diseases like Parkinson's disease (PD).
  • Identifying key regulators of microglial activation is crucial for developing effective PD treatments.

Purpose of the Study:

  • To investigate the role of microglial Kv1.3 channels in PD pathogenesis.
  • To explore Fyn kinase as a modulator of Kv1.3 and its therapeutic potential in PD.

Main Methods:

  • Transcriptional analysis of Kv1.3 in microglial cultures and PD models.
  • Electrophysiological studies (patch-clamp) to assess Kv1.3 channel activity.
  • In vivo studies using Kv1.3 knockout models and PAP-1 inhibitor in PD animal models.

Main Results:

  • Microglial Kv1.3 channels were upregulated in response to aggregated alpha-synuclein in PD models and human brains.
  • Fyn kinase directly binds and posttranslationally modifies Kv1.3, enhancing its activity.
  • Inhibition of Kv1.3 with PAP-1 reduced neuroinflammation and neurodegeneration in PD animal models.

Conclusions:

  • Fyn-dependent regulation of Kv1.3 channels is critical for amplifying neuroinflammation in PD.
  • Kv1.3 represents a promising therapeutic target for halting PD progression.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
705
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
835